Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.
Scheich S, Chen J, Liu J, Schnütgen F, Enssle JC, Ceribelli M, Thomas CJ, Choi J, Morris V, Hsiao T, Nguyen H, Wang B, Bolomsky A, Phelan JD, Corcoran S, Urlaub H, Young RM, Häupl B, Wright GW, Huang DW, Ji Y, Yu X, Xu W, Yang Y, Zhao H, Muppidi J, Pan KT, Oellerich T, Staudt LM. Scheich S, et al. Among authors: bolomsky a. Cancer Discov. 2023 Aug 4;13(8):1862-1883. doi: 10.1158/2159-8290.CD-22-1401. Cancer Discov. 2023. PMID: 37141112 Free PMC article.
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
Yang Y, Bolomsky A, Oellerich T, Chen P, Ceribelli M, Häupl B, Wright GW, Phelan JD, Huang DW, Lord JW, Van Winkle CK, Yu X, Wisniewski J, Wang JQ, Tosto FA, Beck E, Wilson K, McKnight C, Travers J, Klumpp-Thomas C, Smith GA, Pittaluga S, Maric I, Kazandjian D, Thomas CJ, Young RM. Yang Y, et al. Among authors: bolomsky a. Nat Commun. 2022 Sep 17;13(1):5469. doi: 10.1038/s41467-022-33142-x. Nat Commun. 2022. PMID: 36115844 Free PMC article.
Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
Yang Y, Bolomsky A, Oellerich T, Chen P, Ceribelli M, Häupl B, Wright GW, Phelan JD, Huang DW, Lord JW, Van Winkle CK, Yu X, Wisniewski J, Wang JQ, Tosto FA, Beck E, Wilson K, McKnight C, Travers J, Klumpp-Thomas C, Smith GA, Pittaluga S, Maric I, Kazandjian D, Thomas CJ, Young RM. Yang Y, et al. Among authors: bolomsky a. Nat Commun. 2022 Oct 3;13(1):5830. doi: 10.1038/s41467-022-33618-w. Nat Commun. 2022. PMID: 36192480 Free PMC article. No abstract available.
Pathogenic signaling in multiple myeloma.
Bolomsky A, Young RM. Bolomsky A, et al. Semin Oncol. 2022 Feb;49(1):27-40. doi: 10.1053/j.seminoncol.2022.01.005. Epub 2022 Jan 20. Semin Oncol. 2022. PMID: 35125242 Free PMC article.
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
Besse L, Besse A, Stolze SC, Sobh A, Zaal EA, van der Ham AJ, Ruiz M, Phuyal S, Büchler L, Sathianathan M, Florea BI, Borén J, Ståhlman M, Huber J, Bolomsky A, Ludwig H, Hannich JT, Loguinov A, Everts B, Berkers CR, Pilon M, Farhan H, Vulpe CD, Overkleeft HS, Driessen C. Besse L, et al. Among authors: bolomsky a. Cancer Res. 2021 Sep 1;81(17):4581-4593. doi: 10.1158/0008-5472.CAN-20-3323. Epub 2021 Jun 22. Cancer Res. 2021. PMID: 34158378 Free PMC article.
25 results